The life sciences industry is one of the most dynamic in the world. The commercial and regulatory environments that it faces are complex, fraught with both opportunity and challenge. At Haug Partners, the combination of our industry experience with our grasp of the legal intricacies facing our life science clients uniquely enables us to understand these challenges, from intellectual property risk and other competitive demands to a sprawling network of global regulation. Our Life Sciences team brings together legal and business expertise to offer comprehensive solutions to our clients operating in the life sciences space, whether they seek to safeguard and increase the value of their intellectual property or bring a new product to the market.
We understand that our clients’ intellectual property is their lifeblood, and we know how important it is to protect their innovations. Our Life Sciences team includes attorneys and scientific advisors with hands-on industry experience and advanced degrees in specialized technical fields, and our interdisciplinary, fully-integrated approach means that we are prepared to assist our clients with all aspects of their businesses, from litigation and alternative dispute resolution to due diligence and compliance planning, patent strategy and prosecution, and antitrust and FDA counseling. We have represented industry-leading pharmaceutical and biotech companies in high-stakes litigation, including Takeda, Supernus, Celgene, Sanofi, and Nektar. Our attorneys have decades of experience helping these clients realize the fullest value of their intellectual property, and we bring this experience to the table at all times.
Haug Partners’ litigation experience has led to many successes for our clients, including significant victories at the summary judgment stage, at trial, and on appeal. Some of our representative industry experience includes work with small molecule and peptide drugs and other pharmaceutical products, and with medical devices such as dermal substitutes, minimally-invasive treatments for cerebrovascular disorders, photodynamic drug-device combinations, standalone in-vitro diagnostic tests, intravascular drug delivery systems, and autoinjector devices. Our antitrust litigators have particular experience defending pharmaceutical innovators against allegations of so-called “reverse payment” settlements, and our nationally-renowned Hatch-Waxman team has successfully represented clients in Paragraph IV challenges against some of the biggest blockbuster drugs in the world. Our focus always remains on our clients, their business objectives and long-term strategies, and their continued success.